There is only one phase I study evaluating EZH2-inhibitors combined with immune checkpoint blockade for a solid tumor including melanoma, lung cancer, and renal cell carcinoma; however, targeting the epigenetic silencing of antigen presentation is an attractive mechanism to induce tumor immunity in pancreatic cancer. Here, EZH2 is linked to neoplasm.